CLJI Worldwide's VIBLOK Addresses Unmet Need in Prevention of Herpes Simplex Virus Transmission in Men and Women

BAY HARBOR ISLANDS, Florida, July 11, 2017 /PRNewswire/ -- CLJI Worldwide reports strong recruitment for the VIBLOK Safety And perFormancE Trial (SAFE Trial).

http://mma.prnewswire.com/media/514341/CLJI_Worldwide_Logo.jpg [http://mma.prnewswire.com/media/514341/CLJI_Worldwide_Logo.jpg]

Please see here for additional information regarding VIBLOK [http://www.viblok.com/].

The CLJI Worldwide SAFE Trial is designed to evaluate the performance of the investigational device, VIBLOK, for adults infected with herpes simplex virus-2 (HSV-2). Over 80% of total study participants are already enrolled in the prospective, comparative multi-center SAFE Trial. Anticipated to last 12 months, the VIBLOK SAFE Trial will likely enroll the required participants ahead of schedule.

Dr. Annet Muetstege, Director of Clinical Affairs at Applied Clinical Services and clinical project manager of the VIBLOK SAFE Trial, emphasized that interest in the SAFE Trial has been remarkable. "In all of my years running clinical trials," says Dr. Muetstege, "I have never seen such fast enrollment and continuous in-flow of interested and eligible subjects."

VIBLOK is a virtually colorless, odorless, and tasteless cream designed to create a protective skin barrier that prevents the passage of viruses (e.g., HSV-2). The SAFE Trial will provide an indication as to whether VIBLOK can safely and effectively block virus passage across the skin in HSV-2 infected people and in doing so, target the currently high prevalence of this sexually transmitted infection (STI) in industrialized and developing countries. If approved, VIBLOK may be used by HSV-2 infected people to prevent spreading the virus, or by non-infected individuals to avoid acquiring the STI.

"The extraordinary interest in the SAFE Trial is indicative of a true unmet need in the prevention of HSV-2 transmission, which VIBLOK has been developed to address," says Ty Cross, President and Chief Executive Officer of CLJI Worldwide.

Across the globe, the prevalence of STIs has continued to increase over time, despite efforts to increase awareness, education, and prevention. Genital herpes, caused by HSV-2, is a common, chronic, recurrent, viral STI affecting over 400 million people worldwide. With women more susceptible than men, approximately 19 million people total are newly infected with HSV-2 annually and carry the disease for life (no treatment exists to eradicate the herpes simplex virus from the body). In comparison to other common STIs (e.g., Chlamydia, Gonorrhoeae and Syphilis), the global prevalence of HSV-2 is higher [1].

In the absence of a cure, treatment of HSV-2 focuses on symptom relief once a genital lesion develops, reducing recurrent episodes of lesion development, and preventing viral transmission between sexual partners. Not only are genital lesions due to HSV-2 often very painful, they also increase the risk of acquiring and transmitting HIV. An HSV-2 seropositive individual is 2-3 times more likely to acquire HIV, while an HIV-infected individual is 3 times more likely to transmit HIV if they are also HSV-2 seropositive [2-8].

In addition to physical symptoms, STIs may cause psychological and psychosexual morbidity. Among some individuals with recurrent genital herpes, a range of emotional responses may be seen, including depression, anguish, distress, anger, diminution of self-esteem and hostility towards the person believed to be the source of infection [9].

"A number of individuals in the trial have shared the emotional distress they experience as a result of having HSV-2," explains Aletha Veenendaal, Principle Investigator at the EB Flevo clinical trial site in The Netherlands. "One trial participant burst into tears as she described her confusion and heartbreak when her ex-boyfriend, who denied giving her HSV-2, left her with recurrent outbreaks." Veenendaal continues, "Now, many years later, she hopes that something positive will come out of her experience."

Despite the use of medical treatments and condoms, genital herpes transmission may still occur through unprotected areas of the skin via micro-sized lesions, which are often exacerbated by grooming practices of the genital area, such as shaving and waxing [10]. Furthermore, while most people with HSV-2 are asymptomatic, viral shedding occurs even when symptoms are not present and can lead to HSV-2 transmission [3]. There is an immediate and growing need for STI prevention as more and more individuals are infected. In the United States, the CDC estimates that almost 20 million new STIs occur each year (50% among people aged 15-24 years old), accounting for nearly $16 billion in health care costs [11].

VIBLOK is an investigational device being evaluated in Europe and the outcomes of this clinical trial will be used to support the product application for CE Mark. It does not have an approved Investigational Device Exemption in the United States.

The SAFE Trial reflects just one of the pioneering studies, sponsored by CLJI Worldwide, that aims at investigating overlooked aspects of healthcare and subsequently solving real problems with scientifically and clinically proven products.

References:


1. Looker KJ et al. Global estimates of prevalent and incident herpes
simplex virus type 2 infections in 2012. PLoS One. 2015 Jan
21;10(1):e114989. doi: 10.1371/journal.pone.0114989.
2. Wald A, Link K. Risk of human immunodeficiency virus infection in herpes
simplex virus type 2-seropositive persons: a meta-analysis. J Infect Dis.
2002; 185: 45-52.
3. Strick LB, Wald A, Celum C. Management of herpes simplex virus type 2
infection in HIV type 1-infected persons. Clin Infect Dis. 2006; 43:
347-56.
4. Celum C, Levine R, Weaver M, Wald A. Genital herpes and human
immunodeficiency virus: double trouble. Bull World Health Organ. 2004;
82: 447-53.
5. Serwadda D, Gray RH, Sewankambo NK, Wabwire-Mangen F, Chen MZ, Quinn TC,
et al. Human immunodeficiency virus acquisition associated with genital
ulcer disease and herpes simplex virus type 2 infection: a nested
case-control study in Rakai, Uganda. J Infect Dis. 2003; 188: 1492-7.
6. Freeman EE, Weiss HA, Glynn JR, Cross PL, Whitworth JA, Hayes RJ. Herpes
simplex virus 2 infection increases HIV acquisition in men and women:
systematic review and meta-analysis of longitudinal studies. AIDS. 2006;
20: 73-83.
7. Reynolds SJ, Quinn TC. Developments in STD/HIV interactions: the
intertwining epidemics of HIV and HSV-2. Infect Dis Clin North Am 2005;
19: 415-25.
8. Reynolds SJ. The role of HSV-2 suppressive therapy for HIV prevention.
Future Microbiol. 2009; 4: 1095-1097.
9. Mindel A, Marks C. Psychological symptoms associated with genital herpes
virus infections: epidemiology and approaches to management. CNS Drugs.
2005;19(4):303-12. Review.
10. Osterberg EC et al. Correlation between pubic hair grooming and STIs:
results from a nationally representative probability sample. Sex Transm
Infect 2016;0:1-5. doi:10.1136/sextrans-2016-052687
11. CDC National Center for HIV/AIDS, Viral Hepatitis, STD and TB
Prevention, Division of STD Prevention. Sexually Transmitted Disease
Surveillance 2015. October 2016


http://mma.prnewswire.com/media/514732/ViBlok_Logo.jpg [http://mma.prnewswire.com/media/514732/ViBlok_Logo.jpg]

Logo - http://mma.prnewswire.com/media/514341/CLJI_Worldwide_Logo.jpg [http://mma.prnewswire.com/media/514341/CLJI_Worldwide_Logo.jpg]

Logo - http://mma.prnewswire.com/media/514732/ViBlok_Logo.jpg [http://mma.prnewswire.com/media/514732/ViBlok_Logo.jpg]

CONTACT: Ty Cross, President and CEO, +1-305-397-8880

Web site: http://www.viblok.com/

PR Newswire

Dit persbericht is via ANP Pers Support naar internationale (vak en online) media gestuurd. Heb je nieuws voor buitenlandse journalisten? Bekijk dan onze mogelijkheden of neem contact met ons op.

Verstuur nu éénmalig een persbericht

Verstuur persberichten en beeldmateriaal naar redacties in binnen- en buitenland. Via het ANP-net, het internationale medianetwerk van PR Newswire of met een perslijst op maat.

Direct persbericht versturen
070 - 41 41 234